Faculty

Alan H. Bryce, M.D.

Location

Phoenix, Arizona

Contact

Bryce.Alan@mayo.edu Clinical Profile

SUMMARY

Alan H. Bryce, M.D., is an oncologist at Mayo Clinic who studies the biology and genetics of prostate cancer. Dr. Bryce's research focuses on identifying new treatments and targeted treatment approaches. His clinical practice centers on prostate cancer and testicular cancer.

Dr. Bryce also is the site director of Mayo Clinic Comprehensive Cancer Center in Arizona.

Focus areas

  • Personalized medicine. With the advent of the Human Genome Project, it has become possible to completely sequence the DNA of a person or their tumor. This technique has the potential to allow doctors to identify a tumor's unique vulnerabilities, to predict which tumors will recur, and to identify which tumors may not require treatment. These methods are ushering in an era in which people receive treatment that is precisely directed at their cancer's most vulnerable point.
  • Use of genomics in prostate cancer. Dr. Bryce is an international leader in developing PARP inhibitors to treat prostate cancer. His work has demonstrated how genetic testing of tumors can help guide tailored, individualized approaches to treatment.
  • Phase I trials. These are trials in which new medicines or new medicine combinations are being tested for the first time. Bringing new medicine into the clinic is a key step in the fight against cancer.

Significance to patient care

Dr. Bryce's research centers on understanding the altered DNA of individual cancer cells, allowing for a precise, targeted treatment strategy. The ultimate goal is to have each tumor biopsied and sequenced, resulting in an individualized treatment plan.

Professional highlights

  • Member, Prostate Cancer Guidelines Panel, National Comprehensive Cancer Network, 2022-present.

  • Prostate Cancer Task Force, National Cancer Institute, 2020-present.
  • International co-principal investigator, A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) clinical trial, 2016-present.
  • Oncology Scholar-in-Training Award, American Association for Cancer Research, Bristol-Myers Squibb, 2009.
  • Outstanding Trainee Award, Hematology, Mayo Clinic, 2009.
  • Young Investigator Award, American Journal of Hematology, 2008.

PROFESSIONAL DETAILS

Primary Appointment

  1. Consultant, Division of Hematology and Medical Oncology, Department of Internal Medicine
  2. Acting Director, Arizona Cancers Programs, Mayo Clinic Cancer Center

Administrative Appointment

  1. Chair, Division of Hematology and Medical Oncology, Department of Internal Medicine

Academic Rank

  1. Professor of Medicine

EDUCATION

  1. Chief Fellow - Hematology/Medical Oncology Mayo Graduate School of Medicine, Mayo Clinic College of Medicine
  2. Fellow - Hematology/Oncology Mayo Graduate School of Medicine, Mayo Clinic College of Medicine
  3. Resident Hematology/Oncology, Programs in Rochester, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
  4. Resident - Internal Medicine Mayo Graduate School of Medicine, Mayo Clinic College of Medicine
  5. Resident Internal Medicine, Programs in Rochester, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
  6. MD Finch University of Health Sciences / Chicago Medical School
  7. BS - Honors in Biochemistry University of California, Los Angeles

Related links

More about research at Mayo Clinic

.
BIO-00028104

Mayo Clinic Footer